v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating expenses:        
Research and development $ 6,811 $ 7,006 $ 13,568 $ 14,784
General and administrative 3,618 3,085 7,463 6,043
Total operating expenses 10,429 10,091 21,031 20,827
Loss from operations (10,429) (10,091) (21,031) (20,827)
Other income (expense)        
Change in fair value of warrant liabilities 2,483 (859) 1,499 (1,366)
Foreign exchange transaction gain 1 0 14 0
Grant income 0 415 0 415
Interest income 138 168 295 378
Interest expense (410) (194) (817) (370)
Total other income (expense), net 2,212 (470) 991 (943)
Net loss (8,217) (10,561) (20,040) (21,770)
Other comprehensive income:        
Foreign currency translation adjustment (4) 74 1 105
Comprehensive loss $ (8,221) $ (10,487) $ (20,039) $ (21,665)
Net loss per common share, basic (in dollars per share) $ (0.43) $ (0.66) $ (1.07) $ (1.50)
Net loss per common share, diluted (in dollars per share) $ (0.43) $ (0.66) $ (1.07) $ (1.50)
Weighted average common shares and pre-funded warrants outstanding, basic (in shares) 19,244,679 16,059,423 18,731,065 14,513,586
Weighted average common shares and pre-funded warrants outstanding, diluted (in shares) 19,244,679 16,059,423 18,731,065 14,513,586